Zacks: Analysts Anticipate Odonate Therapeutics (ODT) Will Post Earnings of -$0.86 Per Share

Equities analysts expect that Odonate Therapeutics (NASDAQ:ODT) will post earnings per share (EPS) of ($0.86) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Odonate Therapeutics’ earnings. The company is scheduled to issue its next earnings results on Wednesday, May 9th.

On average, analysts expect that Odonate Therapeutics will report full year earnings of ($4.30) per share for the current year. For the next year, analysts expect that the firm will report earnings of ($4.46) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Odonate Therapeutics.

Odonate Therapeutics (NASDAQ:ODT) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.14).



Several equities analysts recently commented on ODT shares. Zacks Investment Research cut shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Goldman Sachs started coverage on shares of Odonate Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating and a $27.00 target price for the company. Cowen started coverage on shares of Odonate Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating for the company. Finally, Jefferies Group started coverage on shares of Odonate Therapeutics in a research note on Tuesday, January 2nd. They set a “buy” rating and a $40.00 target price for the company.

In related news, CEO Kevin C. Tang bought 28,612 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was purchased at an average cost of $27.42 per share, for a total transaction of $784,541.04. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Kevin C. Tang acquired 128,255 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was acquired at an average price of $22.47 per share, with a total value of $2,881,889.85. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 310,000 shares of company stock valued at $7,386,567.

Several hedge funds have recently made changes to their positions in ODT. Goldman Sachs Group Inc. acquired a new position in shares of Odonate Therapeutics in the 4th quarter valued at $660,000. RTW Investments LP acquired a new position in shares of Odonate Therapeutics in the 4th quarter valued at $725,000. Chartwell Investment Partners LLC acquired a new position in shares of Odonate Therapeutics in the 4th quarter valued at $755,000. Millennium Management LLC acquired a new position in shares of Odonate Therapeutics in the 4th quarter valued at $2,277,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Odonate Therapeutics in the 4th quarter valued at $2,611,000. Institutional investors own 78.92% of the company’s stock.

NASDAQ ODT opened at $21.09 on Tuesday. The firm has a market cap of $607.03 and a P/E ratio of -9.31. Odonate Therapeutics has a 1 year low of $15.15 and a 1 year high of $32.00.

WARNING: This piece was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://dakotafinancialnews.com/2018/04/13/zacks-analysts-anticipate-odonate-therapeutics-odt-will-post-earnings-of-0-86-per-share.html.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply